Efecto cardioprotector de los inhibidores de sglt2 y agonistas del receptor de glp-1
Resumen
Metodología: Se realizó una revisión narrativa a través de diversas bases de datos de Enero de 2015 a Enero de 2022; la búsqueda y selección de artículos fue llevada a cabo en revistas indexadas en idioma inglés. Se utilizaron como palabras clave: Cardioprotector, inhibidores de SGLT2, agonistas del receptor de GLP-1. Resultados: Los SGLT2i reducen la hemoglobina glicosilada entre un 0,5 % y un 1,0 % demostrando efectos favorables sobre el peso corporal, la presión arterial, el perfil lipídico, la rigidez arterial y la función endotelial. Los análogos del GLP-1 reducen significativamente los valores de la Presión arterial. Los mecanismos fisiológicos por los cuales se llega a una regulación aun no son del todo claras. Se han planteado diversos mecanismos, dentro de los cuales encontramos la activación directa del receptor del GLP-1 en las arterias y el sistema renal, incluida una mejora de la función endotelial, así como un efecto vasodilatador y natriurético. Conclusiones: La presente revisión ofrece información actualizada y detallada sobre los efectos cardioprotectores que son brindados por el uso de los inhibidores de SGLT2 y agonistas del receptor de GLP-1 en pacientes diabéticos, especialmente en aquellos con factores de riesgo de desarrollar enfermedades cardiovasculares.
Descargas
Citas
R. Salvatore, A. Biagio, C. Eusebio. B. Antonio, I. Ciro, P. Daniela. Type 2 Diabetes Mellitus and Cardiovascular Disease: Genetic and Epigenetic Links. Front. Endocrinol., 17 January 2018. https://doi.org/10.3389/fendo.2018.00002
M. Benjamin, M. Thomas. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes. 2015 Oct 10; 6(13): 1246–1258. doi: 10.4239/wjd.v6.i13.1246
J. Robert. Type-2 diabetes mellitus and cardiovascular disease. Future Cardiol. 2018 Nov;14(6):491-509. doi: 10.2217/fca-2018-0045.
F. Wnjun. Epidemiology in diabetes mellitus and cardiovascular disease. Cardiovascular Endocrinology: March 2017-Vol6-Issue1-p8-16. doi: 10.1097/XCE.0000000000000116
M. Ann. Diabetes Mellitus and Cardiovascular Disease. Arteriosclerosis, Thrombosis, And Vascular Biology. https://doi.org/10.1161/ATVBAHA.119.310961
C. Bryce, G. Gordon. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide. Diabetes Metab Syndr Obes. 2019; 12: 2125–2136. doi: 10.2147/DMSO.S212003
S: Daniel, G. Owen, T. William. An Update on SGLT2 Inhibitors for the Treatment of Diabetes Mellitus. Curr Opin Endocrinol Diabetes Obes. 2017 Feb; 24(1): 73–79.doi: 10.1097/MED.0000000000000311
P. Lalita, I. Diana. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 2015; 4: 212283. doi: 10.7573/dic.212283
M. Jennifer, N. Wesley, A. Brooke. GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2021 Mar 9;12:2042018821997320. doi: 10.1177/2042018821997320
T. Anastasios, V. Panayotis, T. Evangelia. SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects. Int J Environ Res Public Health. 2019 Aug 17;16(16):2965. doi: 10.3390/ijerph16162965.
D. Theodosios, L. Angelos, P. Ioanna. SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses. Postgrad Med. 2019 Mar;131(2):82-88. doi: 10.1080/00325481.2019.1581971.
T. Maximilian, R. Johannes, W. Stefan. Cardioprotection by SGLT2 Inhibitors-Does It All Come Down to Na +?. Int J Mol Sci. 2021 Jul 26;22(15):7976. doi: 10.3390/ijms22157976.
N. Maja, Z. Vladimir. J. Jovana. SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms. Heart Fail Rev. 2021 Feb 3. doi: 10.1007/s10741-021-10079-9.
R. Asadur, H. Hirofumi, N. Akira. Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure. Hypertens Res. 2017 Jun;40(6):535-540. doi: 10.1038/hr.2016.193.
M. Chang, C. Sungsoo, Y. Ji, K. Hyeongseok. Cardioprotective Potential of an SGLT2 Inhibitor Against Doxorubicin-Induced Heart Failure. Korean Circ J. 2019 Dec;49(12):1183-1195. doi: 10.4070/kcj.2019.0180.
S. Danubia, Z. Juliano, A. Flavio. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective. Am J Physiol Cell Physiol. 2020 Feb 1;318(2):C328-C336. doi: 10.1152/ajpcell.00275.2019.
D. Gary, V. Subodh. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors. JACC Basic Transl Sci. 2020 Jun; 5(6): 632–644. doi: 10.1016/j.jacbts.2020.02.004
O. Chang-Myung, C. Sungsoo, J. Ji-Yong. Cardioprotective Potential of an SGLT2 Inhibitor Against Doxorubicin-Induced Heart Failure. Korean Circ J. 2019 Dec; 49(12): 1183–1195. doi: 10.4070/kcj.2019.0180
K. Keshac, B. Tapan, K. Arun, A. Sandeep. SGLT-2 Inhibitors: Ideal Remedy for Cardioprotection in Diabetes Mellitus. Curr Mol Pharmacol. 2021 Oct 25;14(4):487-497. doi: 10.2174/1874467213666201012161439.
P. Giuseppe, C. Arturo, V. Erica, P. Pia, G. Raffaele. Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects. Int J Mol Sci. 2021 May 30;22(11):5863. doi: 10.3390/ijms22115863.
P. Milton. Cardioprotective Effects of Sirtuin-1 and Its Downstream Effectors: Potential Role in Mediating the Heart Failure Benefits of SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors. Circ Heart Fail. 2020 Sep;13(9):e007197. doi: 10.1161/CIRCHEARTFAILURE.120.007197.
D. Gary, V. Subodh. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. JACC Basic Transl Sci. 2020 Jun 22;5(6):632-644. doi: 10.1016/j.jacbts.2020.02.004.
L. Sarayut, C. Siriporn, C. Nipon. Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors. Cardiovasc Diabetol. 2018; 17: 101. doi: 10.1186/s12933-018-0745-5.
K. Dimos, C. David, S. DImitrios, T. Aphrodite. Cardio-Protective Effects of Sodium-Glucose Co-Transporter 2 Inhibitors: Focus on Heart Failure. Curr Pharm Des. 2021;27(8):1051-1060. doi: 10.2174/1381612826666201103122813.
O. Utkarsh, R. Lenisse, E. Florence. Diabetes, Heart Failure and Beyond: Elucidating the Cardioprotective Mechanisms of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors. Am J Cardiovasc Drugs. 2022 Jan;22(1):35-46. doi: 10.1007/s40256-021-00486-6.
C. Frank, O. Per. Cardioprotection with Yet Another SGLT2 Inhibitor - An Embarrassment of Riches. N Engl J Med. 2021 Jan 14;384(2):179-181. doi: 10.1056/NEJMe2033176.
U. Saad, R. Faiga. Evidence-Based Clinical Review on Cardiovascular Benefits of SGLT2 (Sodium-Glucose Co-Transporter Type 2) Inhibitors in Type 2 Diabetes Mellitus. Cureus. 2020 Aug; 12(8): e9655. doi: 10.7759/cureus.9655.
J. Maria, W. Jan. Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity. Drugs. 2019 Feb;79(3):219-230. doi: 10.1007/s40265-019-1057-0.
M. Colleen, L. George. Blood Pressure Reduction: An Added Benefit of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes. Diabetes Care, Vol 38, Issue 3, 1 March 2015. https://doi.org/10.2337/dc14-1596.
S. Zsolt, T. Kalman, S. Eszter. The Effects of SGLT2 Inhibitors on Lipid Metabolism. Metabolites. 2021 Feb 1;11(2):87. doi: 10.3390/metabo11020087.
B. Agnes, O. Christian, J. Susanne. How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial. Cardiovasc Diabetol. 2019; 18: 44. doi: 10.1186/s12933-019-0839-8.
D. William, B. Ghazaleh, J. Kelly. Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Vascular Cell Function and Arterial Remodeling. Int J Mol Sci. 2021 Aug; 22(16): 8786. doi: 10.3390/ijms22168786.
M. Sunder. Integrating cardioprotective glucose-lowering medications into clinical practice. Cardiovasc Endocrinol Metab. 2018 Mar; 7(1): 24–27. doi: 10.1097/XCE.0000000000000142
T. Juan. Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments. Eur Cardiol. 2019 Apr; 14(1): 23–32. doi: 10.15420/ecr.2018.34.2
G. Angus, P. Stephen, A. Karin, M. Anna. SGLT-2 Inhibition: Novel Therapeutics for Reno-and Cardioprotection in Diabetes Mellitus. Curr Diabetes Rev. 2019;15(5):349-356. doi: 10.2174/1573399814666180417121246.
N. Yasuaki, K. Koichiro. Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients. J Cardiol. 2020 Aug;76(2):123-131. doi: 10.1016/j.jjcc.2020.03.009.
T. Pongpan, S. Piangkwan, S. Sivaporn. Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury. J Endocrinol. 2018 Feb;236(2):69-84. doi: 10.1530/JOE-17-0457.
R. Lars, F. Giulia, M. Linda. Is cardioprotection with GLP-1 receptor agonists a class effect?. European Journal of Preventive Cardiology, Volume 28, Issue 1, January 2021. https://doi.org/10.1093/eurjpc/zwaa103
A. Asim, A. Noora, Y. Israa. Glucagon-like Peptide-1 Receptor Agonists Cardio-protective Effects: An Umbrella Review. Curr Diabetes Rev. 2020;16(8):820-832. doi: 10.2174/1573399816666200522214554.
I. Maria, J. Juan. GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes. J Diabetes Res. 2018; 2018: 4020492. doi: 10.1155/2018/4020492
G. Dario, S. Lorenzo, L. Miriam. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovascular Diabetology. 15 september 2021
A. Eirini, T. Costas, A. Ioannis, L. Ioannis. GLP-1 receptor agonists and cardiovascular outcome trials: An update. Hellenic Journal of Cardiology. Volume 60, Issue 6, November–December 2019, Pages 347-351. https://doi.org/10.1016/j.hjc.2018.11.008.
M. Ahsan, M. Dhanwantee, B. Sanja. M. Abdul. Cardioprotective GLP-1 metabolite prevents ischemic cardiac injury by inhibiting mitochondrial trifunctional protein-α. The Journal of Clinical Investigation. January 27, 2020. Doi: 10.1172/JCI99934
J. Kai, W. Dandan, C. Feng, T. Zizhuo. Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis. Protein Cell. 2021 Jan 8. doi: 10.1007/s13238-020-00809-4.
R. Sahithi, H. Tinaz, H. Hanan, A. Mahmoud. Do SGLT2 Inhibitors Improve Cardio-Renal Outcomes in Patients With Type II Diabetes Mellitus: A Systematic Review. Cureus. 2021 Sep; 13(9): e17668. doi: 10.7759/cureus.17668
Derechos de autor 2022 Jorge Andrés Negrete Levette;Fanny Johanna Villabona Leal;Orlys Patricia Rojas Daza;Yuliana Cuellar Anturi;Fernan Andres Torres Hernandez;Ariel Joaquin Benegas Masi;David Fernando Ortiz Perez;Roberto José Bonfante Villalobos
Esta obra está bajo licencia internacional Creative Commons Reconocimiento 4.0.
.jpg)
.png)
.png)
1.png)
